– Bloomberg
Mizuho Reiterates Buy on Atara Biotherapeutics, Maintains $31 Price Target
Mizuho analyst Salim Syed reiterates Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $31 price target.
Related Posts
HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $50
HC Wainwright & Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $55 to $50.
Why Nio, Xpeng Are Pushing EV Stocks Higher In Hong Kong Today
Shares of Tesla Inc (NASDAQ: TSLA) rivals and U.S.-listed Chinese electric automakers were a mixed bag in the Hong Kong markets on Thursday.
Enhabit Sees FY23 Adj. EPS $0.50-$0.89 Vs $1.14 Est; Net Service Revenue $1.11B-$1.14B Vs $1.11B Est
GUIDANCE
The Company is providing full-year 2023 guidance as follows:
Full-year 2023
Guidance
Net Service